Investigational^↗Metabolic^↗

Amycretin^↗

An amylin and GLP-1 receptor agonist candidate. This profile cites a completed ClinicalTrials.gov study record.^↗

Citation markers ↗ open the public records supporting the adjacent statements.

Profile update · July 27, 2026

We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change. ¹

This version supersedes public version 1.

Evidence summary

What the cited records say

ClinicalTrials.gov lists a Novo Nordisk oral amycretin study as completed, last updated March 5, 2025.^↗

This is a source summary, not a medical recommendation. Status may differ by jurisdiction and product.

Cited context

Related records

Organizations named in cited records

Novo Nordisk A/S^↗

Trial records

NCT06049329 ↗

Dated source history

Updates connected to this profile

No dated update is published for this profile. PeptideScanner does not monitor every source continuously; the current profile summary and cited records remain available below.